A preliminary test using this prototype was carried out and showed encouraging results.
The accuracy of these synthetic time series in terms of the frequency of the most extreme magnitude events is difficult to test using this methodology alone.
The noncommercial ELISA test using this chimeric citrullinated synthetic peptide was more sensitive than the commercial one using CCP1 (82% vs. 65.8%) in an RA population and reacted with some CCP2-negative sera [ 20].
We had the unique opportunity to retest banked sera from a population-based serosurvey, previously examined using the WRAIR gold standard test, using this new assay, to investigate the comparability of the seroepidemiology using a newer method.
The expected ratio of reference DNA to test using this approach is 1 1 over the region of the chromosome not covered by sDp3, 2 3 over the region covered by sDp3 alone and 2 1 in the region of the deficiency balanced by sDp3.
A power test using this variance estimate indicates that a two-sample t-test comparison of control animals (n = 8) versus treated (overuse plus rest) animals (n = 5), has 69% power to detect a fold change of 1.7 at a significance level of 0.05.
